These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28111033)

  • 21. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.
    Lalive PH; Menge T; Delarasse C; Della Gaspera B; Pham-Dinh D; Villoslada P; von Büdingen HC; Genain CP
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2280-5. PubMed ID: 16461459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease.
    Cobo-Calvo A; Sepúlveda M; Rollot F; Armangué T; Ruiz A; Maillart E; Papeix C; Audoin B; Zephir H; Biotti D; Ciron J; Durand-Dubief F; Collongues N; Ayrignac X; Labauge P; Thouvenot E; Bourre B; Montcuquet A; Cohen M; Deschamps R; Solà-Valls N; Llufriu S; De Seze J; Blanco Y; Vukusic S; Saiz A; Marignier R
    J Neuroinflammation; 2019 Jul; 16(1):134. PubMed ID: 31266527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
    Gaertner S; de Graaf KL; Greve B; Weissert R
    Neurology; 2004 Dec; 63(12):2381-3. PubMed ID: 15623705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype.
    Otto F; Moser T; Feige J; Seiberl M; Bieler L; Sellner J
    Mult Scler Relat Disord; 2020 Jul; 42():102108. PubMed ID: 32339987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infectious Mononucleosis Triggers Generation of IgG Auto-Antibodies against Native Myelin Oligodendrocyte Glycoprotein.
    Kakalacheva K; Regenass S; Wiesmayr S; Azzi T; Berger C; Dale RC; Brilot F; Münz C; Rostasy K; Nadal D; Lünemann JD
    Viruses; 2016 Feb; 8(2):. PubMed ID: 26907324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.
    Di Pauli F; Mader S; Rostasy K; Schanda K; Bajer-Kornek B; Ehling R; Deisenhammer F; Reindl M; Berger T
    Clin Immunol; 2011 Mar; 138(3):247-54. PubMed ID: 21169067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Hennes EM; Baumann M; Schanda K; Anlar B; Bajer-Kornek B; Blaschek A; Brantner-Inthaler S; Diepold K; Eisenkölbl A; Gotwald T; Kuchukhidze G; Gruber-Sedlmayr U; Häusler M; Höftberger R; Karenfort M; Klein A; Koch J; Kraus V; Lechner C; Leiz S; Leypoldt F; Mader S; Marquard K; Poggenburg I; Pohl D; Pritsch M; Raucherzauner M; Schimmel M; Thiels C; Tibussek D; Vieker S; Zeches C; Berger T; Reindl M; Rostásy K;
    Neurology; 2017 Aug; 89(9):900-908. PubMed ID: 28768844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity.
    Xu Y; Zhang Y; Liu CY; Peng B; Wang JM; Zhang XJ; Li HF; Cui LY
    Chin Med J (Engl); 2012 Sep; 125(18):3207-10. PubMed ID: 22964310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viability of autoantibody-targets: how to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis.
    Mayer MC; Hohlfeld R; Meinl E
    J Neurol Sci; 2012 Aug; 319(1-2):2-7. PubMed ID: 22647585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of azathioprine treatment on IgG subclasses in multiple sclerosis].
    Losy J; Michałowska-Wender G; Wender M
    Neurol Neurochir Pol; 1993; 27(1):39-44. PubMed ID: 8502358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of anti-Nogo receptor autoantibody in the serum of multiple sclerosis and controls.
    Onoue H; Satoh JI; Ogawa M; Tabunoki H; Yamamura T
    Acta Neurol Scand; 2007 Mar; 115(3):153-60. PubMed ID: 17295709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelin Oligodendrocyte Glycoprotein-IgG-positive Recurrent Bilateral Optic Papillitis with Serous Retinal Detachment.
    Kon T; Hikichi H; Ueno T; Suzuki C; Nunomura J; Kaneko K; Takahashi T; Nakashima I; Tomiyama M
    Intern Med; 2018 Nov; 57(22):3307-3312. PubMed ID: 29780155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?
    Lee DH; Linker RA
    Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MOG Antibodies in Pediatric Neurology.
    Huppke P
    Neuropediatrics; 2018 Feb; 49(1):1-2. PubMed ID: 28915516
    [No Abstract]   [Full Text] [Related]  

  • 36. Failure of alemtuzumab therapy to control MOG encephalomyelitis.
    Wildemann B; Jarius S; Schwarz A; Diem R; Viehöver A; Hähnel S; Reindl M; Korporal-Kuhnke M
    Neurology; 2017 Jul; 89(2):207-209. PubMed ID: 28600462
    [No Abstract]   [Full Text] [Related]  

  • 37. Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity.
    Amin M; Mays M; Polston D; Flanagan EP; Prayson R; Kunchok A
    J Neuroimmunol; 2021 Dec; 361():577743. PubMed ID: 34695769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
    Jurynczyk M; Geraldes R; Probert F; Woodhall MR; Waters P; Tackley G; DeLuca G; Chandratre S; Leite MI; Vincent A; Palace J
    Brain; 2017 Mar; 140(3):617-627. PubMed ID: 28364548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OMG: MS, NMOSD, and MOG.
    Lewis SL
    Continuum (Minneap Minn); 2019 Jun; 25(3):594-595. PubMed ID: 31162306
    [No Abstract]   [Full Text] [Related]  

  • 40. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.
    Jarius S; Ruprecht K; Stellmann JP; Huss A; Ayzenberg I; Willing A; Trebst C; Pawlitzki M; Abdelhak A; Grüter T; Leypoldt F; Haas J; Kleiter I; Tumani H; Fechner K; Reindl M; Paul F; Wildemann B
    J Neuroinflammation; 2018 Mar; 15(1):88. PubMed ID: 29554927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.